Karolinska Development AB ser.B (KDEV)

Sell: 0.847 SEK|Buy: 0.85 SEK|Change: 0.01 (-0.82%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Open

0.853 SEK

Previous close

0.854 SEK

Trade high

0.86 SEK

Volume

70,226

Year high

1.50 SEK

Year low

0.80 SEK

Dividend yield

–

Market capitalisation

228.55 mn SEK

P/E ratio

10.76

ISIN

SE0002190926

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA

Share price

Performance 21/10/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Karolinska Development AB ser.B	- 0.82
More...

Company profile

Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved, and commercializes the innovations through the sales of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.